Treatment of advanced breast cancer with 20 mg toremifene, a phase II study. Preliminary communication.
Fourteen postmenopausal women with estrogen-receptor positive advanced breast cancer and no prior cytostatic treatment received 20 mg toremifene daily as a single dose after a loading dose (120----60----60 mg) for the first 3 days. All were evaluable and had undergone at least 6 weeks' treatment. Results were: no complete remissions (CR), 3 partial remissions (PR), 8 no change (NC) and 3 cases of progressive disease (PD). Three patients had mild side effects: nausea, insomnia, sweating and arm pain.
Pyrhönen
S
S
Department of Radiotherapy and Oncology, Helsinki, University Central Hospital, Finland.
Valavaara
R
R
Heikkinen
M
M
Rissanen
P
P
Blanco
G
G
Nordman
E
E
Holsti
L R
LR
Hajba
A
A
D000368:Aged; D001799:Blood Sedimentation / Q000187:drug effects; D001943:Breast Neoplasms / Q000188:drug therapy*; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D004965:Estrogen Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008875:Middle Aged; D013629:Tamoxifen / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017312:Toremifene
D004965:Estrogen Antagonists; D013629:Tamoxifen; D017312:Toremifene